• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

转基因小鼠表明肿瘤促进需要AP-1(激活蛋白-1)反式激活。

Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion.

作者信息

Young M R, Li J J, Rincón M, Flavell R A, Sathyanarayana B K, Hunziker R, Colburn N

机构信息

Basic Research Laboratory, National Cancer Institute, Frederick, MD 21702, USA.

出版信息

Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9827-32. doi: 10.1073/pnas.96.17.9827.

DOI:10.1073/pnas.96.17.9827
PMID:10449779
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC22295/
Abstract

Activator protein-1 (AP-1) is a transcription factor that consists of either a Jun-Jun homodimer or a Jun-Fos heterodimer. Transactivation of AP-1 is required for tumor promoter-induced transformation in mouse epidermal JB6 cells and for progression in mouse and human keratinocytes. Until now, the question of whether AP-1 transactivation is required for carcinogenesis in vivo has remained unanswered, as has the issue of functionally significant target genes. To address these issues we have generated a transgenic mouse in which transactivation mutant c-jun (TAM67), under the control of the human keratin-14 promoter, is expressed specifically in the basal cells of the epidermis where tumor induction is initiated. The keratin-14-TAM67 transgene was expressed in the epidermis, tongue, and cervix, with no apparent abnormalities in any tissue or organ. TAM67 expression blocked 12-O-tetradecanoylphorbol 13-acetate (TPA, phorbol 12-tetradecanoate 13-acetate) induction of the AP-1-regulated luciferase in AP-1 luciferase/TAM67 mice, but did not inhibit induction of candidate AP-1 target genes, collagenase-1 or stromelysin-3. More interestingly, TAM67 expression did not inhibit TPA-induced hyperproliferation. In two-stage skin carcinogenesis experiments, the transgenic animals showed a dramatic inhibition of papilloma induction. We conclude that transactivation of a subset of AP-1-dependent genes is required for tumor promotion and may be targeted for cancer prevention.

摘要

活化蛋白-1(AP-1)是一种转录因子,由Jun-Jun同源二聚体或Jun-Fos异源二聚体组成。在小鼠表皮JB6细胞中,肿瘤启动子诱导的转化以及小鼠和人类角质形成细胞的进展都需要AP-1的反式激活。到目前为止,AP-1反式激活在体内致癌过程中是否必需的问题仍未得到解答,功能上具有重要意义的靶基因问题也是如此。为了解决这些问题,我们构建了一种转基因小鼠,其中在人角蛋白-14启动子的控制下,反式激活突变体c-jun(TAM67)在肿瘤诱导起始的表皮基底细胞中特异性表达。角蛋白-14-TAM67转基因在表皮、舌头和子宫颈中表达,任何组织或器官均无明显异常。在AP-1荧光素酶/TAM67小鼠中,TAM67的表达阻断了12-O-十四烷酰佛波醇13-乙酸酯(TPA,佛波醇12-十四烷酸酯13-乙酸酯)诱导的AP-1调节的荧光素酶,但不抑制候选AP-1靶基因胶原酶-1或基质金属蛋白酶-3的诱导。更有趣的是,TAM67的表达并不抑制TPA诱导的过度增殖。在两阶段皮肤致癌实验中,转基因动物的乳头状瘤诱导受到显著抑制。我们得出结论,AP-1依赖性基因的一个子集的反式激活是肿瘤促进所必需的,并且可能是癌症预防的靶点。

相似文献

1
Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion.转基因小鼠表明肿瘤促进需要AP-1(激活蛋白-1)反式激活。
Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9827-32. doi: 10.1073/pnas.96.17.9827.
2
Dominant-negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation.显性负性c-Jun(TAM67)靶基因:肿瘤启动子诱导的转化需要HMGA1。
Oncogene. 2004 May 27;23(25):4466-76. doi: 10.1038/sj.onc.1207581.
3
Dominant-negative activator protein 1 (TAM67) targets cyclooxygenase-2 and osteopontin under conditions in which it specifically inhibits tumorigenesis.显性负性激活蛋白1(TAM67)在特异性抑制肿瘤发生的条件下靶向环氧化酶-2和骨桥蛋白。
Cancer Res. 2007 Mar 15;67(6):2430-8. doi: 10.1158/0008-5472.CAN-06-0522.
4
A dominant negative mutant of jun blocking 12-O-tetradecanoylphorbol-13-acetate-induced invasion in mouse keratinocytes.一种Jun的显性负性突变体,可阻断12-O-十四烷酰佛波醇-13-乙酸酯诱导的小鼠角质形成细胞侵袭。
Mol Carcinog. 1997 Jul;19(3):204-12. doi: 10.1002/(sici)1098-2744(199707)19:3<204::aid-mc8>3.0.co;2-d.
5
Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes.显性负性Jun的表达可抑制升高的AP-1和NF-κB反式激活,并抑制人乳头瘤病毒永生化人角质形成细胞的锚定非依赖性生长。
Oncogene. 1998 May 28;16(21):2711-21. doi: 10.1038/sj.onc.1201798.
6
Induced expression of dominant-negative c-jun downregulates NFkappaB and AP-1 target genes and suppresses tumor phenotype in human keratinocytes.显性负性c-jun的诱导表达下调NFκB和AP-1靶基因,并抑制人角质形成细胞中的肿瘤表型。
Mol Carcinog. 2000 Nov;29(3):159-69. doi: 10.1002/1098-2744(200011)29:3<159::aid-mc5>3.0.co;2-w.
7
Tumor promoter-induced ornithine decarboxylase gene expression occurs independently of AP-1 activation.肿瘤启动子诱导的鸟氨酸脱羧酶基因表达独立于AP-1激活而发生。
Oncogene. 1999 Oct 14;18(42):5806-13. doi: 10.1038/sj.onc.1202965.
8
c-jun and multistage carcinogenesis: association of overexpression of introduced c-jun with progression toward a neoplastic endpoint in mouse JB6 cells sensitive to tumor promoter-induced transformation.c-jun与多阶段致癌作用:在对肿瘤启动子诱导转化敏感的小鼠JB6细胞中,导入的c-jun过表达与向肿瘤终点进展的关联。
Mol Carcinog. 1995 May;13(1):27-36. doi: 10.1002/mc.2940130106.
9
bcl-2 enhancement of malignant transformation in mouse epidermal JB6 cells.bcl-2增强小鼠表皮JB6细胞的恶性转化。
Mol Carcinog. 1997 Oct;20(2):231-9. doi: 10.1002/(sici)1098-2744(199710)20:2<231::aid-mc10>3.0.co;2-b.
10
Inhibition of tumor promoter-induced transformation by retinoids that transrepress AP-1 without transactivating retinoic acid response element.通过反式抑制AP-1而不反式激活视黄酸反应元件的类视黄醇对肿瘤启动子诱导的转化的抑制作用。
Cancer Res. 1996 Feb 1;56(3):483-9.

引用本文的文献

1
The universal role of adaptive transcription in health and disease.适应性转录在健康与疾病中的普遍作用。
FEBS J. 2025 May;292(10):2479-2505. doi: 10.1111/febs.17324. Epub 2024 Nov 28.
2
Vitamin A resolves lineage plasticity to orchestrate stem cell lineage choices.维生素 A 解决谱系可塑性以协调干细胞谱系选择。
Science. 2024 Mar 8;383(6687):eadi7342. doi: 10.1126/science.adi7342.
3
The CaSR Modulator NPS-2143 Reduced UV-Induced DNA Damage in Skh:hr1 Hairless Mice but Minimally Inhibited Skin Tumours.钙敏感受体调节剂 NPS-2143 减少了 Skh:hr1 无毛小鼠的 UV 诱导的 DNA 损伤,但对皮肤肿瘤的抑制作用很小。
Int J Mol Sci. 2023 Mar 3;24(5):4921. doi: 10.3390/ijms24054921.
4
The Use of Retinoids for the Prevention and Treatment of Skin Cancers: An Updated Review.类视黄醇在皮肤癌的预防和治疗中的应用:最新综述。
Int J Mol Sci. 2022 Oct 20;23(20):12622. doi: 10.3390/ijms232012622.
5
Synthetic lethal kinases in Ras/p53 mutant squamous cell carcinoma.Ras/p53 突变型鳞状细胞癌中的合成致死激酶。
Oncogene. 2022 Jun;41(24):3355-3369. doi: 10.1038/s41388-022-02330-w. Epub 2022 May 10.
6
The Fra-1/AP-1 Oncoprotein: From the "Undruggable" Transcription Factor to Therapeutic Targeting.Fra-1/AP-1癌蛋白:从“不可成药”的转录因子到治疗靶点
Cancers (Basel). 2022 Mar 14;14(6):1480. doi: 10.3390/cancers14061480.
7
Signaling of MK2 sustains robust AP1 activity for triple negative breast cancer tumorigenesis through direct phosphorylation of JAB1.MK2的信号传导通过直接磷酸化JAB1维持强大的AP1活性,促进三阴性乳腺癌的肿瘤发生。
NPJ Breast Cancer. 2021 Jul 9;7(1):91. doi: 10.1038/s41523-021-00300-1.
8
BACH2-mediated FOS confers cytarabine resistance via stromal microenvironment alterations in pediatric ALL.BACH2 介导的 FOS 通过改变小儿 ALL 中的基质微环境赋予阿糖胞苷耐药性。
Cancer Sci. 2021 Mar;112(3):1235-1250. doi: 10.1111/cas.14792. Epub 2021 Jan 22.
9
Transcriptional and signalling regulation of skin epithelial stem cells in homeostasis, wounds and cancer.皮肤上皮干细胞在稳态、创伤和癌症中的转录和信号调控。
Exp Dermatol. 2021 Apr;30(4):529-545. doi: 10.1111/exd.14247. Epub 2020 Dec 11.
10
A Driver Never Works Alone-Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human Cancer.驱动因素从不单独起作用——人类癌症中突变型p53、MYC、RAS及其他常见致癌驱动因素的相互作用网络
Cancers (Basel). 2020 Jun 11;12(6):1532. doi: 10.3390/cancers12061532.

本文引用的文献

1
Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes.显性负性Jun的表达可抑制升高的AP-1和NF-κB反式激活,并抑制人乳头瘤病毒永生化人角质形成细胞的锚定非依赖性生长。
Oncogene. 1998 May 28;16(21):2711-21. doi: 10.1038/sj.onc.1201798.
2
Chemopreventive effect of difluoromethylornithine (DFMO) on mouse skin squamous cell carcinomas induced by benzo(a)pyrene.二氟甲基鸟氨酸(DFMO)对苯并(a)芘诱导的小鼠皮肤鳞状细胞癌的化学预防作用。
J Cell Biochem Suppl. 1997;28-29:81-9.
3
Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB.转基因上皮组织中核因子-κB功能的改变表明核因子-κB具有生长抑制作用。
Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2307-12. doi: 10.1073/pnas.95.5.2307.
4
A dominant negative mutant of jun blocking 12-O-tetradecanoylphorbol-13-acetate-induced invasion in mouse keratinocytes.一种Jun的显性负性突变体,可阻断12-O-十四烷酰佛波醇-13-乙酸酯诱导的小鼠角质形成细胞侵袭。
Mol Carcinog. 1997 Jul;19(3):204-12. doi: 10.1002/(sici)1098-2744(199707)19:3<204::aid-mc8>3.0.co;2-d.
5
Both conserved region 1 (CR1) and CR2 of the human papillomavirus type 16 E7 oncogene are required for induction of epidermal hyperplasia and tumor formation in transgenic mice.人乳头瘤病毒16型E7癌基因的保守区域1(CR1)和保守区域2(CR2)都是转基因小鼠诱导表皮增生和肿瘤形成所必需的。
J Virol. 1997 Aug;71(8):5905-14. doi: 10.1128/JVI.71.8.5905-5914.1997.
6
Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid.维甲酸的抗肿瘤促进作用需要阻断激活蛋白-1的活性,而不是激活维甲酸反应元件。
Proc Natl Acad Sci U S A. 1997 May 27;94(11):5826-30. doi: 10.1073/pnas.94.11.5826.
7
Urokinase-mediated transactivation of the plasminogen activator inhibitor type 2 (PAI-2) gene promoter in HT-1080 cells utilises AP-1 binding sites and potentiates phorbol ester-mediated induction of endogenous PAI-2 mRNA.尿激酶介导的人纤维肉瘤细胞系(HT-1080细胞)中纤溶酶原激活物抑制剂2(PAI-2)基因启动子的反式激活利用了活化蛋白-1(AP-1)结合位点,并增强了佛波酯介导的内源性PAI-2信使核糖核酸(mRNA)的诱导作用。
FEBS Lett. 1997 Feb 3;402(2-3):265-72. doi: 10.1016/s0014-5793(97)00002-1.
8
AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44.AP-1介导的侵袭需要增加透明质酸受体CD44的表达。
Mol Cell Biol. 1997 Feb;17(2):963-76. doi: 10.1128/MCB.17.2.963.
9
Transgenic studies with a keratin promoter-driven growth hormone transgene: prospects for gene therapy.利用角蛋白启动子驱动生长激素转基因的转基因研究:基因治疗的前景。
Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):219-26. doi: 10.1073/pnas.94.1.219.
10
Altered expression of insulin-like growth factor I and its receptor during multistage carcinogenesis in mouse skin.胰岛素样生长因子I及其受体在小鼠皮肤多阶段致癌过程中的表达变化。
Mol Carcinog. 1996 Oct;17(2):62-9. doi: 10.1002/(SICI)1098-2744(199610)17:2<62::AID-MC2>3.0.CO;2-V.